DOSAGE INDEX / SINGLE
DSIP
Research, reported schedules and supply planning.
Compare small DSIP sleep studies, including favorable early signals and weak insomnia results, with careful attention to timing, function and safety gaps.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
Reported example 1
- Amount
- 100–300 micrograms per day; a separate example reaches 500 micrograms
- Frequency
- Once daily
- Cycle / observation period
- 4–8 weeks; source also mentions 12 weeks
- Route / research model
- Subcutaneous
The 10 mg vial page uses a different course length.
Reported example 2
- Amount
- 100–300 micrograms per day
- Frequency
- Once daily
- Cycle / observation period
- 8–12 weeks
- Route / research model
- Subcutaneous
The 5 mg vial page uses a different course length and includes a higher-dose example.
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 5 mg | Enter a total |
| 10 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- DSIP stands for delta sleep-inducing peptide. The name describes a research history, not a guaranteed sleep effect. Small human experiments reported favorable sleep findings, while another controlled study found weak effects and questioned their therapeutic importance. [1] [2]
- A 1981 double-blind crossover experiment studied six healthy volunteers. After morning intravenous DSIP, the researchers reported more sleep within a 130-minute observation period and favorable changes in some subsequent nighttime measures. No adverse effects were observed in that small experiment. The sample and short observation period cannot establish uncommon harms or general insomnia efficacy. [1]
- A 1987 placebo-controlled, double-blind study examined 14 middle-aged people with chronic insomnia over seven treatment nights. The author reported improved nighttime sleep and daytime alertness and performance, with some sleep effects continuing into the first post-treatment placebo night. This was a small, short study, even though it assessed both nighttime and daytime outcomes. [3]
- FDA identifies potential immunogenicity and characterization concerns for compounded emideltide, also called DSIP, and reports missing safety information for the proposed route. [4]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 60 entries mapped from 2 source pages. Medical and supporting references are retained below; supplier entries are excluded.
- Early volunteer study
- 1992 insomnia study
- Original 24-hour sleep-wake study
- FDA safety resource
- Schoenenberger GA, Monnier M (1977)Further reading · Listed in reference bibliography.
- European Journal of Anaesthesiology (2001)Further reading · Listed in reference bibliography.
- Schneider-Helmert D, Schoenenberger GA (1983)Further reading · Listed in reference bibliography.
- Sudakov KV et al. (2004)Further reading · Listed in reference bibliography.
- Graf MV, Kastin AJ (1984)Further reading · Listed in reference bibliography.
- Iyer KS et al. (1988)Further reading · Listed in reference bibliography.
- Manning MC et al. (2010)Further reading · Listed in reference bibliography.
- Wang W (2000)Further reading · Listed in reference bibliography.
- Yehuda S, Carasso RL (1988)Further reading · Listed in reference bibliography.
- Khvatova EM et al. (2003)Further reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
- Proceedings of the National Academy of Sciences (PubMed) Original characterization and sequence context for delta sleep-inducing peptideFurther reading · Listed in reference bibliography.
- Human Chronic-Insomnia Study (PubMed) Single 25 nmol/kg IV exposure in six middle-aged patients with chronic insomniaFurther reading · Listed in reference bibliography.
- Human Endocrine Study in Healthy Men (PubMed) Single 25 nmol/kg IV exposure in 11 healthy menFurther reading · Listed in reference bibliography.
- Human Endocrine and Circadian Study in Healthy Women (PubMed) Single 25 mcg/kg IV infusion over 30 minutesFurther reading · Listed in reference bibliography.
- European Journal of Anaesthesiology — Delta sleep-inducing peptide: discovery, structure, and pharmacological overviewFurther reading · Listed in reference bibliography.
- Neuroscience & Biobehavioral Reviews (PubMed) — Delta-sleep-inducing peptide (DSIP): a review of sleep-promoting and neuromodulatory effectsFurther reading · Listed in reference bibliography.
- European Neurology (PubMed) — DSIP in insomnia: timing and frequency of administration in clinical trialsFurther reading · Listed in reference bibliography.
- MedlinePlus (U.S. National Library of Medicine) — Subcutaneous (SQ) injections: technique, site selection, and procedureGeneral guidance · Listed in reference bibliography.
- Frontiers in Pharmacology — DSIP fusion peptides crossing the blood-brain barrier and efficacy in insomnia modelsFurther reading · Listed in reference bibliography.
- European Neurology (PubMed) — Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic pain episodesFurther reading · Listed in reference bibliography.
- European Neurology (PubMed) — DSIP in the treatment of withdrawal syndromes from alcohol and opiatesFurther reading · Listed in reference bibliography.
- Johns Hopkins Arthritis Center — How to give a subcutaneous injection: site rotation and best practicesGeneral guidance · Listed in reference bibliography.
- NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration)Further reading · Listed in reference bibliography.
- Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous routeFurther reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.